India Waives Local Trials: Exemption for Investigational Medical Devices with EU Clearance
In a major regulatory update for India’s MedTech sector, the Union Ministry of Health and Family Welfare has officially notified amendments to the Medical Devices Rules (MDR), 2017. The final notification expands clinical trial exemptions for non-predicate devices to include European Union (EU) approvals and introduces mandatory Quality Management System (QMS) requirements for Class A non-sterile and non-measuring medical devices.
Leverage EU Approvals for CDSCO Exemptions
1. EU Approval Added for Rule 63 Clinical Trial Exemptions
Under Rule 63 of the MDR, 2017, manufacturers or importers applying to register a medical device without a predicate device in India are typically required to conduct local clinical investigations and submit safety data to the Central Licensing Authority (CLA).
However, the fourth proviso of Sub-rule (1) of Rule 63 provides an exemption mechanism. Previously, this waiver applied only to investigational devices approved by regulatory bodies in the United States, United Kingdom, Australia, Canada, or Japan.
Key Provisions of the Amendment:
Inclusion of European Union Countries: Devices approved by EU regulatory authorities now qualify for the clinical investigation exemption under Rule 63.
Two-Year Marketing Requirement: To qualify for the waiver, the investigational device must have been legally marketed in the recognized jurisdiction for at least two years.
Safety & Surveillance Evaluation: The Central Licensing Authority must be satisfied with the submitted safety, performance, and post-market pharmacovigilance data.
Trade Facilitation Alignment: This move aligns with broader trade measures established under the India-EU Free Trade Agreement, aiming to reduce technical barriers to trade and align India’s device regulatory framework with global best practices.
2. Mandatory QMS Self-Certification for Class A Medical Devices
The notification also introduces significant compliance updates for low-risk devices. Amendments to Rule 19H and Rule 19J of the MDR, 2017, modify the registration process for Class A (non-sterile and non-measuring) medical devices.
Importers and domestic manufacturers registering Class A devices must now submit proof of Quality Management System (QMS) compliance alongside technical product standards as part of their self-certification documentation to the regulator.
3. Administrative Updates and Implementation Timeline
Testing Laboratory Designation: Rule 19 has been amended to substitute the marginal heading “Central Medical Device Testing Laboratory” with “Government Medical Device Testing Laboratories.”
Finalization Process: The draft rules were originally published in April 2026 for public consultation. Following the evaluation of industry feedback, the Ministry issued the final notification dated August 14, 2026, which is now officially in effect.
How Operon Strategist Can Help
With the latest MDR 2017 amendments granting clinical waivers for EU-approved devices and enforcing strict QMS self-certification for Class A devices, medical device manufacturers and importers must align their technical dossiers with updated CDSCO expectations. Operon Strategist provides end-to-end regulatory consulting to streamline approvals and maximize the benefits of these new regulatory exemptions.
Our key services include:
CDSCO Medical Device Registration: Expert management of manufacturing and import licensing, classification reviews, and regulatory submissions under the Medical Devices Rules, 2017.
Quality Management System (ISO 13485 / QMS): Designing and implementing audit-ready QMS frameworks to meet mandatory Class A self-certification and manufacturing site audit requirements.
CE Marking (EU MDR / IVDR): Securing European Union regulatory approvals to leverage international recognition for fast-tracked access to the Indian market.
Regulatory Due Diligence for Medical Devices: Evaluating global product documentation and predicate status to minimize approval timelines and lower regulatory submission costs.
Our experienced regulatory team works closely with global MedTech companies, Indian manufacturers, and importers to navigate complex CDSCO requirements and accelerate commercialization.
Fast-track your CDSCO approvals with expert regulatory guidance
Get Your Medical Device Market-Ready with Expert Regulatory Support